CORCEPT THERAPEUTICS I
54.30
07-November-24 14:59:58
15 minutes delayed
Stocks
+0.07
+0.13%
Today's range
53.65 - 55.24
ISIN
N/A
Source
NASDAQ
-
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
11 Oct 2022 15:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
03 Aug 2022 15:05:00 By Nasdaq GlobeNewswire
-
29 Jun 2022 15:05:00 By Nasdaq GlobeNewswire
-
06 Jun 2022 07:00:02 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces First Quarter Financial Results And Provides Corporate Update
05 May 2022 15:05:01 By Nasdaq GlobeNewswire
-
28 Apr 2022 15:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Appointment of Three Senior Leaders
07 Apr 2022 15:05:00 By Nasdaq GlobeNewswire
-
04 Apr 2022 15:05:00 By Nasdaq GlobeNewswire
-
30 Mar 2022 15:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
01 Mar 2022 15:05:01 By Nasdaq GlobeNewswire
-
15 Feb 2022 15:05:00 By Nasdaq GlobeNewswire
-
08 Feb 2022 15:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer
20 Dec 2021 15:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer
16 Dec 2021 07:00:02 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares
15 Dec 2021 07:00:01 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
08 Dec 2021 07:00:01 By Nasdaq GlobeNewswire
-
08 Nov 2021 07:30:01 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update
03 Nov 2021 15:05:02 By Nasdaq GlobeNewswire
-
27 Oct 2021 15:05:01 By Nasdaq GlobeNewswire
-
17 Sep 2021 07:30:00 By Nasdaq GlobeNewswire